- Home
- ABTS vs BTAI Comparison
ABTS vs BTAI Comparison
Compare ABTS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- BTAI
- Stock Information
- Founded
- ABTS 2010
- BTAI 2017
- Country
- ABTS Hong Kong
- BTAI United States
- Employees
- ABTS N/A
- BTAI N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- BTAI Health Care
- Exchange
- ABTS Nasdaq
- BTAI Nasdaq
- Market Cap
- ABTS 9.8M
- BTAI 8.3M
- IPO Year
- ABTS N/A
- BTAI 2018
- Fundamental
- Price
- ABTS $4.21
- BTAI $5.48
- Analyst Decision
- ABTS
- BTAI Strong Buy
- Analyst Count
- ABTS 0
- BTAI 4
- Target Price
- ABTS N/A
- BTAI $40.00
- AVG Volume (30 Days)
- ABTS 16.7K
- BTAI 22.4M
- Earning Date
- ABTS 08-13-2025
- BTAI 08-12-2025
- Dividend Yield
- ABTS N/A
- BTAI N/A
- EPS Growth
- ABTS N/A
- BTAI N/A
- EPS
- ABTS N/A
- BTAI N/A
- Revenue
- ABTS $7,037,156.00
- BTAI $868,000.00
- Revenue This Year
- ABTS N/A
- BTAI N/A
- Revenue Next Year
- ABTS N/A
- BTAI $328.13
- P/E Ratio
- ABTS N/A
- BTAI N/A
- Revenue Growth
- ABTS 31.69
- BTAI N/A
- 52 Week Low
- ABTS $1.35
- BTAI $1.17
- 52 Week High
- ABTS $14.10
- BTAI $13.36
- Technical
- Relative Strength Index (RSI)
- ABTS 49.33
- BTAI 67.45
- Support Level
- ABTS $3.87
- BTAI $1.30
- Resistance Level
- ABTS $4.44
- BTAI $8.08
- Average True Range (ATR)
- ABTS 0.33
- BTAI 1.23
- MACD
- ABTS 0.00
- BTAI 0.33
- Stochastic Oscillator
- ABTS 65.74
- BTAI 61.65
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.